Document Detail


Combination of calcium channel blockers and beta-blockers for patients with exercise-induced angina pectoris: beneficial effect of calcium channel blockers largely determined by their effect on heart rate.
MedLine Citation:
PMID:  10392329     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The combination of calcium channel blockers and beta-blockers is more effective for the treatment of exercise-induced angina pectoris than beta-blocker monotherapy. As ischemia in exercise-induced angina is essentially preceded by an increase in heart rate, calcium channel blockers with a negative chronotropic property may perform better for this purpose than nonchronotropic compounds. A 335-patient, 10-week, double-blind, parallel-group comparison of amlodipine 5 mg and 10 mg, diltiazem 200 mg and 300 mg, and mibefradil 50 mg and 100 mg treatment added to baseline beta-blocker treatment was performed. Exercise testing (ETT) was performed by bicycle ergometry. All of the calcium channels blockers significantly delayed the onset of 1 mm ST-segment depression on ETT (p < 0.001 for any treatment vs. baseline). In addition, mibefradil, in both low- and high-dose treatments, produced the largest delays (low dose: different from diltiazem and amlodipine by 24.1 and 29.8 seconds, respectively, p < 0.003 and < 0.001; high dose: different from diltiazem and amlodipine by 33.7 and 37.0 seconds, respectively, p < 0.001 and < 0.001). A stepwise logistic regression analysis revealed that this beneficial effect of calcium channel blockers was largely dependent on their effect on heart rate. Serious symptoms of dizziness likewise occurred significantly more frequently on mibefradil (p < 0.05 vs. diltiazem) and urged no fewer than 19 patients on mibefradil to withdraw from the trial. The authors conclude that calcium channel blockers with a negative chronotropic property provide a better delay of ischemia in patients with exercise-induced angina, but the concomitant risk of intolerable dizziness may reduce this benefit.
Authors:
T J Cleophas; J van der Sluijs; J A van der Vring; M C Daniëls; K J Holwerda; A J Withagen; A Schelling; M G Hendriks; A H Zwinderman
Related Documents :
3825889 - Endorphins are related to pain perception in coronary artery disease.
7904559 - Clinical features of an anti-anginal drug in angina pectoris.
6404149 - Comparison of slow-release pindolol, standard pindolol, and propranolol in angina pecto...
22801449 - The contribution of inspiratory muscles function to exercise limitation in heart failur...
6439019 - Failure of transdermal nitroglycerin to improve chronic stable angina: a randomized, pl...
12412819 - Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in he...
23537269 - Characteristics of patients with severe heart failure exhibiting exercise oscillatory v...
22523249 - Cardiac resynchronization therapy mediated effects on exercise left ventricular functio...
17473779 - Effect of vibration training in maximal effort (70% 1rm) dynamic bicep curls.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  39     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-08-18     Completed Date:  1999-08-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  738-46     Citation Subset:  IM    
Affiliation:
The Netherlands Working Group on Cardiovascular Research (WCN), Dordrecht.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adrenergic beta-Antagonists / adverse effects,  therapeutic use*
Adult
Aged
Amlodipine / therapeutic use
Angina Pectoris / drug therapy*,  etiology
Benzimidazoles / therapeutic use
Calcium Channel Blockers / adverse effects,  therapeutic use*
Death, Sudden / etiology
Diltiazem / therapeutic use
Dizziness / chemically induced
Double-Blind Method
Drug Therapy, Combination
Exercise*
Exercise Test
Female
Heart Rate / drug effects
Humans
Male
Mibefradil
Middle Aged
Regression Analysis
Tetrahydronaphthalenes / therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Benzimidazoles; 0/Calcium Channel Blockers; 0/Tetrahydronaphthalenes; 116644-53-2/Mibefradil; 42399-41-7/Diltiazem; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pharmacokinetic and pharmacodynamic action of etodolac in patients after oral surgery.
Next Document:  Helicobacter pylori and endoscopy.